PacBio’s Q1 results and lowered 2024 revenue outlook have prompted a downgrade from JPMorgan. The company’s shares have fallen in premarket trading on Monday. JPMorgan has withdrawn its price target on the stock and believes that the macro backdrop will continue to affect placements and margins in the near term.